| 前收市價 | 283.40 |
| 開市 | 283.60 |
| 買盤 | 286.40 x 0 |
| 賣出價 | 287.00 x 0 |
| 今日波幅 | 282.80 - 287.80 |
| 52 週波幅 | 189.03 - 302.00 |
| 成交量 | |
| 平均成交量 | 552,496 |
| 市值 | 96.998B |
| Beta 值 (5 年，每月) | 0.26 |
| 市盈率 (最近 12 個月) | 45.23 |
| 每股盈利 (最近 12 個月) | 6.31 |
| 業績公佈日 | 2024年7月16日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 344.80 |
ZacksAll You Need to Know About Swedish Orphan Biovitrum (BIOVF) Rating Upgrade to Strong Buy
Swedish Orphan Biovitrum (BIOVF) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BenzingaEuropean Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B
Swedish Orphan Biovitrum AB (OTC: BIOVF) has agreed to acquire CTI BioPharma (NASDAQ: CTIC) for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction price represents an 89% premium to CTI's closing share price on May 9, 2023, and a 95% premium to its 30-trading day volume-weighted average price of $4.67. The transaction will diversify Sobi's portfolio of hematology medicines through CTI's lead product, Von
